Related Experiment Video
Updated: Sep 9, 2025

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Biomarkers and neuroimaging markers in Parkinson's disease
Dongning Su1, Yuanchu Zheng2, Tao Feng1,2
1Center for Movement Disorders, Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Abstract:
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide, highlighting the urgent need for improved diagnostic and therapeutic strategies. Biomarkers from cerebrospinal fluid (CSF), blood, and peripheral tissue hold promise for early PD detection. In addition, neuroimaging techniques, including magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), and positron emission tomography (PET), allow for detailed visualization of neurodegeneration and associated structural and functional brain changes. This review summarizes recent advances in PD biomarkers and neuroimaging, highlighting their diagnostic potential and implications for future research.
Related Concept Videos
Neural Regulation
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

